Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aphton (apht) -- Ignore unavailable to you. Want to Upgrade?

To: ButcherBoy who wrote (65)	5/6/1998 12:03:00 PM
From: rocket	Read Replies (1) \| Respond to of 95

Well, it seems some money is coming into the biotech sector (at long last) in response to the news about advances being made in the treatment of cancer. Aphton is up nicely today and is just waiting to be discovered by analysts and other investors. After the street realizes APHT has had excellent results with gastrimmune in phases 1&2 and is almost 2 full years into phase 3 trials, the stock should do well. Add to this that a collaborative agreement may be signed with a major pharm for Gonadimmune sometime in the next 2 months and things should be looking up for this company. Karl